Juglone potentiates TRAIL‑induced apoptosis in human melanoma cells via activating the ROS‑p38‑p53 pathway.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Medicine Reports

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/mmr.2017.7806PMID 29039537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Icariside II overcomes TRAIL resistance of melanoma cells through ROS-mediated downregulation of STAT3/cFLIP signaling

  2016cited by this paper
• The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.

  2016cited by this paper
• Activity guided isolation and modification of juglone from Juglans regia as potent cytotoxic agent against lung cancer cell lines

  2015cited by this paper
• Juglone induces cell death of Acanthamoeba through increased production of reactive oxygen species.

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Exploring the antiviral activity of juglone by computational method

  2014cited by this paper
• Targeting death receptors for TRAIL by agents designed by Mother Nature.

  2014cited by this paper
• Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins

  2013cited by this paper
• Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism.

  2012cited by this paper
• Anticancer activity and mechanism of juglone on human cervical carcinoma HeLa cells.

  2012cited by this paper
• Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells.

  2011cited by this paper
• Plumbagin and juglone induce caspase-3-dependent apoptosis involving the mitochondria through ROS generation in human peripheral blood lymphocytes.

  2011cited by this paper
• Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway.

  2010cited by this paper
• TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.

  2009cited by this paper
• Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells

  2009cited by this paper
• TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.

  2009cited by this paper
• The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

  2008cited by this paper
• Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.

  2008cited by this paper
• Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily.

  2008cited by this paper
• Targeting death-inducing receptors in cancer therapy

  2007cited by this paper
• Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.

  2006cited by this paper
• Mechanisms of resistance to TRAIL-induced apoptosis in cancer

  2005cited by this paper
• Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP

  2004cited by this paper
• Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells

  2003cited by this paper
• Receptor-Mediated Choreography of Life and Death

  2003cited by this paper
• The involvement of reactive oxygen species (ROS) and p38 mitogen‐activated protein (MAP) kinase in TRAIL/Apo2L‐induced apoptosis

  2002cited by this paper
• The kiss of death: promises and failures of death receptors and ligands in cancer therapy

  2001cited by this paper
• Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line

  2000cited by this paper
• Antimicrobial activity of extracts of eastern North American hardwood trees and relation to traditional medicine.

  2000cited by this paper
• Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

  2000influential reference
• Oxidative stress and apoptosis.

  2000cited by this paper

• Anti-tumour signalling pathways and molecular targets of 1,4-naphthoquinone-based natural dyes.

  2025cites this paper
• Research Progress of Natural Compounds from Chinese Herbal Medicine in the Treatment of Melanoma

  2025cites this paper
• Juglone and Other Biogenic Quinones Differentially Inhibit Cyanobacterial Growth and Could Be Used to Help Maintain Monospecificity of Microalgae Cultures

  2025cites this paper
• Juglone suppresses vasculogenic mimicry in glioma through inhibition of HuR-mediated VEGF-A expression.

  2024cites this paper
• Primary Melanoma of the Pineal Gland Case Report and Review of the Literature

  2024cites this paper
• Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway

  2024cites this paper
• The Green Walnut Husks Induces Apoptosis of Colorectal Cancer Through Regulating NLRC3/PI3K Pathway.

  2023cites this paper
• Naphthoquinone derivatives targeting melanoma.

  2023cites this paper
• Molecular biological mechanism of action in cancer therapies: Juglone and its derivatives, the future of development.

  2022cites this paper
• Fabrication of Electrospun Juglans regia (Juglone) Loaded Poly(lactic acid) Scaffolds as a Potential Wound Dressing Material

  2022cites this paper
• Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.

  2022cites this paper
• Jug-PLGA-NPs, a New Form of Juglone with Enhanced Efficiency and Reduced Toxicity on Melanoma

  2021cites this paper
• Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease

  2021cites this paper
• Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma

  2021cites this paper
• Potential Anti-Tumor Activity of Kefir-Induced Juglone and Resveratrol Fractions Against Ehrlich Ascites Carcinoma-Bearing BALB/C Mice

  2020cites this paper
• Development of Pin1 inhibitors and their potential as therapeutic agents.

  2020cites this paper
• Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response

  2020cites this paper
• Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway.

  2020cites this paper
• Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway

  2020cites this paper
• ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro.

  2019cites this paper
• Rare encounters: Primary pineal malignant melanoma with lepto-meningeal spread. Case report and literature review on management challenges and outcomes.

  2019cites this paper
• Juglone in Oxidative Stress and Cell Signaling

  2019cites this paper
• Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells.

  2018cites this paper
• Natural Products to Fight Cancer: A Focus on Juglans regia

  2018cites this paper
• p53 and glucose metabolism: an orchestra to be directed in cancer therapy.

  2018cites this paper